Del Chiaro Marco, Segersvärd Ralf, Lohr Matthias, Verbeke Caroline
Marco Del Chiaro, Ralf Segersvärd, Matthias Löhr, Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, 141 86 Stockholm, Sweden.
World J Gastroenterol. 2014 Sep 14;20(34):12118-31. doi: 10.3748/wjg.v20.i34.12118.
Pancreatic cancer is the 4(th) leading cause of cancer-related death in Western countries. Considering the low incidence of pancreatic cancer, population-based screening is not feasible. However, the existence of a group of individuals with an increased risk to develop pancreatic cancer has been well established. In particular, individuals suffering from a somatic or genetic condition associated with an increased relative risk of more than 5- to 10-fold seem to be suitable for enrollment in a surveillance program for prevention or early detection of pancreatic cancer. The aim of such a program is to reduce pancreatic cancer mortality through early or preemptive surgery. Considering the risk associated with pancreatic surgery, the concept of preemptive surgery cannot consist of a prophylactic removal of the pancreas in high-risk healthy individuals, but must instead aim at treating precancerous lesions such as intraductal papillary mucinous neoplasms or pancreatic intraepithelial neoplasms, or early cancer. Currently, results from clinical trials do not convincingly demonstrate the efficacy of this approach in terms of identification of precancerous lesions, nor do they define the outcome of the surgical treatment of these lesions. For this reason, surveillance programs for individuals at risk of pancreatic cancer are thus far generally limited to the setting of a clinical trial. However, the acquisition of a deeper understanding of this complex area, together with the increasing request for screening and treatment by individuals at risk, will usher pancreatologists into a new era of preemptive pancreatic surgery. Along with the growing demand to treat individuals with precancerous lesions, the need for low-risk investigation, low-morbidity operation and a minimally invasive approach becomes increasingly pressing. All of these considerations are reasons for preemptive pancreatic surgery programs to be undertaken in specialized centers only.
在西方国家,胰腺癌是癌症相关死亡的第四大原因。鉴于胰腺癌发病率较低,基于人群的筛查并不可行。然而,已明确存在一组患胰腺癌风险增加的个体。特别是,患有与相对风险增加5至10倍以上相关的体细胞或遗传疾病的个体似乎适合纳入胰腺癌预防或早期检测的监测项目。此类项目的目的是通过早期或预防性手术降低胰腺癌死亡率。考虑到胰腺手术相关风险,预防性手术的概念不能包括对高危健康个体进行胰腺预防性切除,而必须旨在治疗癌前病变,如导管内乳头状黏液性肿瘤或胰腺上皮内瘤变,或早期癌症。目前,临床试验结果并未令人信服地证明这种方法在识别癌前病变方面的有效性,也未明确这些病变手术治疗的结果。因此,迄今为止,针对胰腺癌高危个体的监测项目通常仅限于临床试验环境。然而,随着对这一复杂领域的深入理解,以及高危个体对筛查和治疗需求的增加,胰腺病学家将迎来预防性胰腺手术的新时代。随着治疗癌前病变个体需求的增加,对低风险检查、低发病率手术和微创方法的需求变得越来越迫切。所有这些因素都表明,预防性胰腺手术项目应仅在专科中心开展。